About: Comparison of commercial lateral flow immunoassays and ELISA for SARS-CoV-2 antibody detection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comparison of commercial lateral flow immunoassays and ELISA for SARS-CoV-2 antibody detection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Comparison of commercial lateral flow immunoassays and ELISA for SARS-CoV-2 antibody detection
Creator	Affiliations, Serrano, Maria Mochón, Ocete Dolores, Mª Arenas, Roberto Palop, Nuria Cardona, Concepción, Gimeno Moreno Córdoba, Marta Navalpotro Rodríguez, David Toran, Alfred
source	Elsevier; Medline; PMC
abstract	BACKGROUND: COVID-19 pandemic has spread worldwide since December 2019. Serological tests for SARS-CoV-2 antibody testing are needed for detection of current or past infections. A wide range of commercial tests is available. However, most of them need to be validated. STUDY DESIGN: The aim was to compare a commercial IgG and IgA ELISA (Euroimmun) with three lateral flow immunoassays (LFI): Hangzhou Alltest Biotech, Wuhan UNscience Biotechnology and Guangzhou Wondfo Biotech. Specificity was calculated with 62 available serum samples from 2018/19. The study included 152 sera from patients of which 109 were RT-PCR positive. Sensitivities for ELISA anti SARS-CoV-2 IgG and IgA were 81,5% and 93,1% and specificities 100% and 80,6%, respectively. LFI showed variable performances, overall results being better for Guangzhou Wondfo Biotech. CONCLUSIONS: Commercial serological tests are useful for detection of antibodies in patients with COVID-19. ELISA presented better results than LFI. The results allowed to incorporate the most sensitive LFI to the daily workflow, combining with ELISA. Careful validation is encouraged before clinical laboratories start using these tests.
has issue date	2020-06-29(xsd:dateTime)
bibo:doi	10.1016/j.jcv.2020.104529
bibo:pmid	32659710
has license	no-cc
sha1sum (hex)	72ff9c3fdc0a6e2510b7c6b6b014b564f29a9e09
schema:url	https://doi.org/10.1016/j.jcv.2020.104529
resource representing a document's title	Comparison of commercial lateral flow immunoassays and ELISA for SARS-CoV-2 antibody detection
has PubMed Central identifier	PMC7323682
has PubMed identifier	32659710
schema:publication	J Clin Virol
resource representing a document's body	covid:72ff9c3fdc0a6e2510b7c6b6b014b564f29a9e09#body_text
is schema:about of	named entity 'detection' named entity 'band' named entity 'IgM' named entity 'IgG' named entity 'IgA' named entity 'lateral' named entity 'Writing' named entity 'Martínez' named entity 'Investigation' named entity 'Data curation' named entity 'Comparison' named entity 'Maria' named entity 'compare' named entity 'needed' named entity '2018' named entity 'samples' named entity 'IgG' named entity 'serum' named entity 'wide range' named entity 'LFI' named entity 'samples' named entity 'calculated' named entity 'patients' named entity 'Guangzhou' named entity 'improved' named entity 'symptoms' named entity 'Data curation' named entity 'Methodology' named entity 'Guangzhou' named entity 'COVID-19 pandemic' named entity 'antibody testing' named entity 'Wuhan' named entity 'IgG' named entity 'IgG' named entity 'serum samples' named entity 'IgG' named entity 'Data curation' named entity 'immunoassays' named entity 'antibody' named entity 'Data curation' named entity 'validated' named entity 'COVID' named entity 'Asymptomatic patients' named entity 'contact tracing' named entity 'gene' named entity 'Guangzhou' named entity 'long-term' named entity 'antibodies' named entity 'COVID-19' named entity 'real-time PCR' named entity 'glycoprotein' named entity 'LFI' named entity 'serum samples' named entity 'asymptomatic' named entity 'serum' named entity 'IgG' named entity 'WHO' named entity 'LFI' named entity 'IgM' named entity 'COVID' named entity 'RT-PCR' named entity 'coronavirus' named entity 'infectious disease' named entity 'seroconversion' named entity 'lateral flow immunoassay' named entity 'RT-PCR' named entity 'antibodies' named entity 'tested positive' named entity 'serological' named entity 'LFI' named entity 'Biotech'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software